Feed BTCY
BT

Biotricity, Inc. BTCY · OTC

$0.05 -4.55% (-$0.00)

Summary

49 / 100 · Bulios Score

What speaks for it

  • Revenue grew by 18% a year over the last 3 years.
  • The share price is below the Bulios Fair Price.

What to watch

  • The company made a loss over the last 12 months.
  • Operating profit does not even cover the interest on its debt.

Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more

Score in detail

Price

Is it expensive?

Looks cheap
Bulios Fair Price
Current price $0.053

Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?

The company made a loss over the last 12 months, so there is no profit to set the price against.

Valuation in detail

Is it growing?

Yes, fast

Revenue (USD)

Diluted EPS (USD)

Revenue grew by 36% a year over 5 years. Over the last 3 years it grew by 18% a year.

Growth in detail

Does it make money?

Reasonably

Over the last 12 months it made a loss of $2.80M.

Profitability in detail

Is it financially healthy?

Debt is a burden

Repaying all its debt would take 161.2 years of free cash flow. Its debt is larger than its cash.

Financial health in detail

Does it pay a dividend?

No

It pays no dividend.

Dividends in detail

What do analysts expect?

Mildly positive

Today's price within the analysts' price targets

The average target of $4 is 7,519% above today's price. 50% of the analysts recommend buying.

Analysts in detail

What does it earn on?

Fiscal year 2026

By product

By region

The company reports no revenue by region.

Technology Fees brings in 90% of revenue. Device Sales grew fastest, by 12% a year.

Segments in detail

We use essential cookies to run the website and optional analytics cookies to measure usage.

Privacy policy